Global Acute Ischemic Stroke Therapeutics Market Insights, Forecast to 2025

Description:

AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternative therapies, extensive use of generics, and unmet needs for anticoagulant reversal agents.

Technavio's analysts forecast the global acute ischemic stroke therapeutics market to grow at a CAGR of 2.11% during the period 2017-2025.

The global Acute Ischemic Stroke Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of 0.021 during 2019-2025. The objectives of this study are to define, segment, and project the size of the Acute Ischemic Stroke Therapeutics market based on company, product type, end user and key regions.

This report studies the global market size of Acute Ischemic Stroke Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Acute Ischemic Stroke Therapeutics in these regions.

This research report categorizes the global Acute Ischemic Stroke Therapeutics market by top players/brands, region, type and end user. This report also studies the global Acute Ischemic Stroke Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

Bayer
Boehringer Ingelheim
Roche
Sanofi
Biogen
Daiichi Sankyo
Pfizer

Market size by Product
Thrombolytic Therapeutics
Antihypertensive Therapeutics
Antiplatelet Therapeutics
Anticoagulants

Market size by End User
Hospitals
Ambulatory Surgical Center
Diagnostic Centers

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Acute Ischemic Stroke Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Acute Ischemic Stroke Therapeutics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry specific challenges and risks).
Focuses on the key global Acute Ischemic Stroke Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Acute Ischemic Stroke Therapeutics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Acute Ischemic Stroke Therapeutics are as follows:
- History Year: 2014-2018
- Base Year: 2018
- Estimated Year: 2019
- Forecast Year: 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Acute Ischemic Stroke Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

### Table of Contents

#### 1 Study Coverage
- 1.1 Acute Ischemic Stroke Therapeutics Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
  - 1.4.1 Global Acute Ischemic Stroke Therapeutics Market Size Growth Rate by Product
  - 1.4.2 Thrombolytic Therapeutics
  - 1.4.3 Antihypertensive Therapeutics
  - 1.4.4 Antiplatelet Therapeutics
  - 1.4.5 Anticoagulants
- 1.5 Market by End User
  - 1.5.1 Global Acute Ischemic Stroke Therapeutics Market Size Growth Rate by End User
  - 1.5.2 Hospitals
  - 1.5.3 Ambulatory Surgical Center
  - 1.5.4 Diagnostic Centers
- 1.6 Study Objectives
- 1.7 Years Considered

#### 2 Executive Summary
- 2.1 Global Acute Ischemic Stroke Therapeutics Market Size
  - 2.1.1 Global Acute Ischemic Stroke Therapeutics Revenue 2014-2025
  - 2.1.2 Global Acute Ischemic Stroke Therapeutics Sales 2014-2025
- 2.2 Acute Ischemic Stroke Therapeutics Growth Rate by Regions
  - 2.2.1 Global Acute Ischemic Stroke Therapeutics Sales by Regions
  - 2.2.2 Global Acute Ischemic Stroke Therapeutics Revenue by Regions

#### 3 Breakdown Data by Manufacturers
- 3.1 Acute Ischemic Stroke Therapeutics Sales by Manufacturers
  - 3.1.1 Acute Ischemic Stroke Therapeutics Sales by Manufacturers
  - 3.1.2 Acute Ischemic Stroke Therapeutics Sales Market Share by Manufacturers
  - 3.1.3 Global Acute Ischemic Stroke Therapeutics Market Concentration Ratio (CRS and HHI)
- 3.2 Acute Ischemic Stroke Therapeutics Revenue by Manufacturers
  - 3.2.1 Acute Ischemic Stroke Therapeutics Revenue by Manufacturers (2014-2019)
  - 3.2.2 Acute Ischemic Stroke Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.3 Acute Ischemic Stroke Therapeutics Price by Manufacturers
- 3.4 Acute Ischemic Stroke Therapeutics Manufacturing Base Distribution, Product Types
  - 3.4.1 Acute Ischemic Stroke Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
  - 3.4.2 Manufacturers Acute Ischemic Stroke Therapeutics Product Type
  - 3.4.3 Date of International Manufacturers Enter into Acute Ischemic Stroke Therapeutics Market
  - 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

#### 4 Breakdown Data by Product
- 4.1 Global Acute Ischemic Stroke Therapeutics Sales by Product
- 4.2 Global Acute Ischemic Stroke Therapeutics Revenue by Product
- 4.3 Acute Ischemic Stroke Therapeutics Price by Product

#### 5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Acute Ischemic Stroke Therapeutics Breakdown Data by End User

#### 6 North America
- 6.1 North America Acute Ischemic Stroke Therapeutics by Countries
  - 6.1.1 North America Acute Ischemic Stroke Therapeutics Sales by Countries
  - 6.1.2 North America Acute Ischemic Stroke Therapeutics Revenue by Countries
  - 6.1.3 United States
  - 6.1.4 Canada
  - 6.1.5 Mexico
- 6.2 North America Acute Ischemic Stroke Therapeutics by Product
- 6.3 North America Acute Ischemic Stroke Therapeutics by End User
7 Europe

- 7.1 Europe Acute Ischemic Stroke Therapeutics by Countries
  - 7.1.1 Europe Acute Ischemic Stroke Therapeutics Sales by Countries
  - 7.1.2 Europe Acute Ischemic Stroke Therapeutics Revenue by Countries
  - 7.1.3 Germany
  - 7.1.4 France
  - 7.1.5 UK
  - 7.1.6 Italy
  - 7.1.7 Russia
- 7.2 Europe Acute Ischemic Stroke Therapeutics by Product
- 7.3 Europe Acute Ischemic Stroke Therapeutics by End User

8 Asia Pacific

- 8.1 Asia Pacific Acute Ischemic Stroke Therapeutics by Countries
  - 8.1.1 Asia Pacific Acute Ischemic Stroke Therapeutics Sales by Countries
  - 8.1.2 Asia Pacific Acute Ischemic Stroke Therapeutics Revenue by Countries
  - 8.1.3 China
  - 8.1.4 Japan
  - 8.1.5 Korea
  - 8.1.6 India
  - 8.1.7 Australia
  - 8.1.8 Indonesia
  - 8.1.9 Malaysia
  - 8.1.10 Philippines
  - 8.1.11 Thailand
  - 8.1.12 Vietnam
  - 8.1.13 Singapore
- 8.2 Asia Pacific Acute Ischemic Stroke Therapeutics by Product
- 8.3 Asia Pacific Acute Ischemic Stroke Therapeutics by End User

9 Central & South America

- 9.1 Central & South America Acute Ischemic Stroke Therapeutics by Countries
  - 9.1.1 Central & South America Acute Ischemic Stroke Therapeutics Sales by Countries
  - 9.1.2 Central & South America Acute Ischemic Stroke Therapeutics Revenue by Countries
  - 9.1.3 Brazil
- 9.2 Central & South America Acute Ischemic Stroke Therapeutics by Product
- 9.3 Central & South America Acute Ischemic Stroke Therapeutics by End User

10 Middle East and Africa

- 10.1 Middle East and Africa Acute Ischemic Stroke Therapeutics by Countries
  - 10.1.1 Middle East and Africa Acute Ischemic Stroke Therapeutics Sales by Countries
  - 10.1.2 Middle East and Africa Acute Ischemic Stroke Therapeutics Revenue by Countries
  - 10.1.3 GCC Countries
  - 10.1.4 Turkey
  - 10.1.5 Egypt
  - 10.1.6 South Africa
- 10.2 Middle East and Africa Acute Ischemic Stroke Therapeutics by Product
- 10.3 Middle East and Africa Acute Ischemic Stroke Therapeutics by End User

11 Company Profiles

- 11.1 Bayer
  - 11.1.1 Bayer Company Details
  - 11.1.2 Company Business Overview
  - 11.1.4 Bayer Acute Ischemic Stroke Therapeutics Products Offered
  - 11.1.5 Bayer Recent Development
- 11.2 Boehringer Ingelheim
  - 11.2.1 Boehringer Ingelheim Company Details
  - 11.2.2 Company Business Overview
  - 11.2.3 Boehringer Ingelheim Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
  - 11.2.4 Boehringer Ingelheim Acute Ischemic Stroke Therapeutics Products Offered
  - 11.2.5 Boehringer Ingelheim Recent Development
- 11.3 Roche
  - 11.3.1 Roche Company Details
  - 11.3.2 Company Business Overview
  - 11.3.3 Roche Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
  - 11.3.4 Roche Acute Ischemic Stroke Therapeutics Products Offered
  - 11.3.5 Roche Recent Development
- 11.4 Sanofi
  - 11.4.1 Sanofi Company Details
  - 11.4.2 Company Business Overview
  - 11.4.3 Sanofi Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
  - 11.4.4 Sanofi Acute Ischemic Stroke Therapeutics Products Offered
  - 11.4.5 Sanofi Recent Development
- 11.5 Biogen
  - 11.5.1 Biogen Company Details
  - 11.5.2 Company Business Overview
  - 11.5.3 Biogen Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
  - 11.5.4 Biogen Acute Ischemic Stroke Therapeutics Products Offered
  - 11.5.5 Biogen Recent Development
- 11.6 Daiichi Sankyo
  - 11.6.1 Daiichi Sankyo Company Details
  - 11.6.2 Company Business Overview
  - 11.6.4 Daiichi Sankyo Acute Ischemic Stroke Therapeutics Products Offered
11.6.5 Daiichi Sankyo Recent Development

11.7 Pfizer
   11.7.1 Pfizer Company Details
   11.7.2 Company Business Overview
   11.7.3 Pfizer Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
   11.7.4 Pfizer Acute Ischemic Stroke Therapeutics Products Offered
   11.7.5 Pfizer Recent Development

12 Future Forecast
   12.1 Acute Ischemic Stroke Therapeutics Market Forecast by Regions
      12.1.1 Global Acute Ischemic Stroke Therapeutics Sales Forecast by Regions 2019-2025
      12.1.2 Global Acute Ischemic Stroke Therapeutics Revenue Forecast by Regions 2019-2025
   12.2 Acute Ischemic Stroke Therapeutics Market Forecast by Product
      12.2.1 Global Acute Ischemic Stroke Therapeutics Sales Forecast by Product 2019-2025
      12.2.2 Global Acute Ischemic Stroke Therapeutics Revenue Forecast by Product 2019-2025
   12.3 Acute Ischemic Stroke Therapeutics Market Forecast by End User
   12.4 North America Acute Ischemic Stroke Therapeutics Forecast
   12.5 Europe Acute Ischemic Stroke Therapeutics Forecast
   12.6 Asia Pacific Acute Ischemic Stroke Therapeutics Forecast
   12.7 Central & South America Acute Ischemic Stroke Therapeutics Forecast
   12.8 Middle East and Africa Acute Ischemic Stroke Therapeutics Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
   13.1 Market Opportunities and Drivers
   13.2 Market Challenges
   13.3 Market Risks/Restraints
   13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
   14.1 Value Chain Analysis
   14.2 Acute Ischemic Stroke Therapeutics Customers
   14.3 Sales Channels Analysis
      14.3.1 Sales Channels
      14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
   16.1 Research Methodology
      16.1.1 Methodology/Research Approach
      16.1.2 Data Source
   16.2 Author Details